Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Today, Cephalon, Inc. announced the signing of a convertible note subscription agreement with ChemGenex Pharmaceuticals Limited, an Australian-based oncology focused biopharmaceutical company.

22 Oct 2010

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genmab A/S announced today that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010 were approximately DKK 78 million (approximately USD 14 million).

21 Oct 2010

Cord Blood to explain queries on VoiceAmerica Radio Network

Cord Blood America, Inc. the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. Geoffrey O'Neill, Vice President, Operations, will appear for one hour live on "Go Rogue & Get Rich" on The VoiceAmerica Radio Network.

21 Oct 2010

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and nine months ended September 30, 2010.

21 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

Partnership between institutions in high- and low-resource areas can improve pediatric sarcoma treatment

Raising the survival rate of children with sarcoma in low-income countries will require steps to diagnose the disease sooner, train cancer pathologists, expand radiation therapy services, create multi-specialty teams to review each case, and other actions, according to an international study led by Dana-Farber/Children's Hospital Cancer Center researchers. The findings will be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Friday, Oct. 22.

21 Oct 2010

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

Genoptix ranked #41 on Deloitte's Technology Fast 500

Genoptix, Inc., a specialized laboratory services provider, today announced that it ranked number 41 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2005–2009. Genoptix grew 3,451 percent during this period.

20 Oct 2010

USPTO grants two additional patents to Ryogen

Ryogen LLC, a genomic research and development company focusing on genes with applications in biomedical research, has been awarded two additional patents on human genes.

20 Oct 2010

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

The US Department of Defense (DOD) has awarded a $5 million grant to The Feinstein Institute for Medical Research and the University of Cincinnati to further develop a "lab-on-a-chip" device used for monitoring patients suffering from severe brain injury.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Studies and analyses of the Crohn's disease (CD) treatment Cimzia (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 – 20.

18 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

EntreMed receives letter from NASDAQ Stock Market

EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).

15 Oct 2010

New development of genetic tool to speed discovery of novel genes involved in cancer

Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes.

15 Oct 2010

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

Stem cells, the prodigious precursors of all the tissues in our body, can make almost anything, given the right circumstances. Including, unfortunately, cancer. Now research from Rockefeller University shows that having too many stem cells, or stem cells that live for too long, can increase the odds of developing cancer.

15 Oct 2010

First national educational conference on Graft vs. Host Disease

The Case Comprehensive Cancer Center, together with the Meredith A. Cowden Foundation, will bring the first national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Thursday, Nov. 4, 8 a.m. to 6 p.m., at Corporate College East, 4400 Richmond Road, Warrenville Hts. GvHD is a life-threatening complication experienced by an estimated 60 percent of all leukemia and other blood cancer patients following bone marrow transplantation. There is currently no cure.

14 Oct 2010

Scientists unveil quality control mechanism of immune system to destroy pathogens

An Australian team of scientists has uncovered a quality control mechanism that must take place for our immune system to subsequently effectively destroy harmful viruses and bacteria.

14 Oct 2010

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

13 Oct 2010

Leukemia News and Research

Further Reading

Cephalon signs convertible note subscription agreement with ChemGenex Pharmaceuticals

Genmab A/S reports DKK 78 million in net sales for Arzerra

Cord Blood to explain queries on VoiceAmerica Radio Network

Alexion 2010 third quarter revenue increases from $102.6 to $141.6 million

LSUHSC receives NIH grant for research on cancer and infectious diseases

Partnership between institutions in high- and low-resource areas can improve pediatric sarcoma treatment

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Genoptix ranked #41 on Deloitte's Technology Fast 500

USPTO grants two additional patents to Ryogen

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

EntreMed receives letter from NASDAQ Stock Market

New development of genetic tool to speed discovery of novel genes involved in cancer

ARTS protein increases apoptosis mechanism to balance stem cells' regenerative power: Research

First national educational conference on Graft vs. Host Disease

Scientists unveil quality control mechanism of immune system to destroy pathogens

New evidence supports possible link between XMRV and prostate cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News